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Abstract 
Purpose: Dysregulation of hedgehog pathway is observed in numerous cancers. Relevance of hedgehog 
pathway genes in cancer cohort and inhibition of its downstream effector (GLI1) towards metastasis in 
cell lines are explored in the study. 
Method: 150 fresh tumours of breast cancer patients were collected for the study. Based on differential 
expression, panel of 6 key regulators of the pathway (SHH, DHH, IHH, PTCH1, SMO and GLI1) in 
microarray datasets were identified. Expressional profiles of aforementioned genes were later correlated 
with clinico-pathological parameters in Pakistani breast cancer cohort at transcript and protein levels. In 
addition, GLI1 over expressing breast cancer cell lines (MDA-MB-231 and MCF-7) were treated with 
GANT61 to explore its probable effects on metastasis.   
Result: SHH, DHH, PTCH1 and GLI1 were significantly over-expressed in tumours as compared with 
respective normal mammary tissues. A significant correlation of SHH, DHH and GLI1 expression with 
advanced tumour size, stages, grades, nodal involvement and distant metastasis was observed (p<0.05). 
Over-expression of SHH, DHH and GLI1 was significantly related with patients having early onset and 
pre-menopausal status. Of note, hedgehog pathway was frequently up regulated in luminal B and triple 
breast cancer negative subtypes affected women. In addition, positive correlations were observed among 
aforementioned members of pathway and Ki67 emphasizing their role towards disease progression. 
Exposure of GANT61 (inhibitor for GLI1) significantly restricted cell proliferation, reduced cell motility 
and invasion. 
Conclusion: Role of activated hedgehog pathway in breast cancer metastasis provides a novel target for 
cancer therapy against aggressive cancer subtypes. 
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Introduction 
Breast cancer is among the most common malignancies accounting for 25% of total cancer burden and 
15% of cancer related deaths [1]. Recently, reactivation of early developmental pathways in promoting 
solid tumour growth has been observed [2]. Pivotal role of hedgehog pathway in embryonic patterning 
and later mammary gland development has been reported [3]. Briefly, binding of three ligands Sonic 
hedgehog (SHH), Indian hedgehog (IHH) and Desert hedgehog (DHH) with Patched1 (PTCH1) results in 
release of Smoothened (SMO). Once relieved SMO activates GLI ((glioma-associated oncogene homolog 
1, transcription factor) responsible for activation of several downstream growth effectors [3].  
Numerous studies suggested dysregulation of hedgehog pathway has an important impact on 
carcinogenesis [4–6]. Exploring any probable correlation of hedgehog pathway with clinico-pathological 
parameters is a step forward towards development of prognostic and predictive markers for future 
therapeutics. Earlier, SHH and GLI1 over-expression have been associated with poor prognosis in 
different types of cancers including breast [6,7], colon [8], glioma [9] and prostate [10]. However, 
prognostic significance of hedgehog pathway with early disease onset and different molecular subtypes of 
breast cancer remain contradictory. Furthermore, its contribution towards metastasis by using cancer cell 
lines is yet to be established. Aim of the study was initially to observe hedgehog pathway activation both 
at mRNA and protein levels in the cohort. Based on these findings, significance of hedgehog pathway in 
breast cancer metastasis was explored using GANT61 (GLI antagonist). Blockade of GLI1 via GANT61 
will be helpful to provide novel insight for involvement of hedgehog pathway in disease progression. 
Results 
Clinical and molecular characterization of cohort 
In Oncomine, 2 datasets TCGA Breast and Finak Breast were assessed for expression variation of 
hedgehog pathway molecules in deposited data. SHH was significantly over-expressed in TCGA 
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(F.C=1.5, p<0.05) and Finak dataset (F.C=1.2, p<0.0001) as compared to normal tissues. Expression of 
PTCH1 (F.C=2.3, p<0.0001) and GLI1 (F.C=2.2, p<0.0001) was also significantly elevated in Finak 
dataset (Suppl. Fig.1). Elevated expression of DHH, PTCH1, and GLI1 in the data deposited for TCGA 
provisional dataset in cBioPortal was also observed. 
Demographic data of present study cohort comprised of 52% of patients having early disease onset and 
were ≤45 yrs of age at the time of diagnosis. Around 60% of cohort represented moderately differentiated 
tumours. Two third of total cases were in advance stages of breast carcinogenesis. Distribution of these 
details along with clinical findings and assessment of hedgehog pathway are presented in the table 1. For 
transcriptional analysis, fold change was evaluated relative to normal control tissues whose mean was 
calculated as 1. 
Significant over expression of SHH (R.E=4.4±3.32), DHH (R.E=4.7±3.46), PTCH1 (R.E=3.4±3.08) and 
GLI1 (R.E=3.8±2.49) were detected in the breast tumour biopsies as compared with controls. In contrast, 
IHH (R.E=0.04±0.16) expression was significantly reduced in cancerous tissues. Lack of any significant 
association of SMO expression among tumour and controls were observed. PTCH1, SHH, DHH, and 
GLI1 over-expression were observed in 74%, 95%, 92% and 98% tumour specimens of the cohort. 
Expression patterns of these genes at mRNA and protein levels along with heatmap of qPCR data are 
shown in figure 1.  
Correlation of Hedgehog Pathway with patients having early disease onset and pre-menopausal 
status 
In both datasets of Oncomine (TCGA breast and Finak breast) expression of SHH, DHH and GLI1 was 
higher in patients having early disease onset. Expression of SHH and GLI1 was also elevated in patients 
having pre-menopausal status while DHH was higher in post-menopausal cases. In the current study, 
cohort elevated expression of SHH (R.E=5.6±3.9, p<0.05), DHH (R.E=5.5±4.1, p<0.05), SMO 
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(R.E=1.9±2.2, p<0.05) and GLI1 (R.E=6.3±4.5, p<0.05) correlated significantly with patients having 
early disease onset. Similarly, expression of SHH (R.E=6.8±4.8, p<0.05), DHH (R.E=5.5±3.9, 
p<0.05)and GLI1(R.E=7.9±4.4, p<0.01)was significantly elevated in pre-menopausal patients while 
PTCH1(R.E=3.9±3.3, p<0.01)was higher in post-menopausal (Fig. 2). 
Correlation of Hedgehog Pathway with markers of poor prognosis 
Over expression of SHH, DHH and GLI1 were associated with cell grades in Finak dataset and also 
related with poorly differentiated tumours. Similarly, transcript copy numbers of SHH and DHH were 
also found related with advanced stages (III, IV). Elevated transcriptional profiles of SHH, DHH and 
GLI1 were associated with almost all indicators of poor prognosis in this cohort. Expression of SHH 
(p<0.05) was 9 folds higher and GLI1 (p<0.05) was 4 folds higher in patients presented with poorly 
differentiated histological grade. Mean mRNA values of SHH, DHH and GLI1 showed gradual increase 
with tumour size, nodal spread and distant metastasis. Significant correlation was observed between SHH 
(R.E=12.76±5.12, p<0.0001), DHH (R.E=9.8±5.1, p<0.05) and GLI1 (R.E=12.3±3.9, p<0.0001) and 
invasive tumour size (Fig. 2).Expression variation of hedgehog pathway and its association with clinico-
pathological parameters is illustrated in table 1. SHH, DHH and GLI1 were also evaluated at protein level 
using IHC. Microscopic features demonstrated cytoplasmic pattern of ligands and nuclear localization of 
GLI1. Tumour sections showed 54%, 65% and 75% positive staining against DHH, SHH, and GLI1 also 
mentioned in the figure1. High intensity of protein expression was observed in patients with advanced 
pTNM stages and poorly differentiated nuclear grade. Hence a consistency of transcriptional profiling 
with protein profiling of SHH, DHH and GLI1 were also established. High expression of all pathway 
components especially GLI1 (HR=1.79 (1.25-2.56), p<0.05) demonstrated significant association with 
shorter DMFS (distant metastasis free survival) in grade III patients (suppl. Fig. 2). This information was 
coherent with expression profile of our dataset rendering hedgehog pathway as a marker of poor 
prognosis. 
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Correlation of Hedgehog Pathway with metastasis and nodal involvement 
Elevated expression of SHH and DHH correlated with N1+ nodal involvement in both datasets. Increase 
in mean copy numbers of SHH and DHH were associated with shorter overall survival in TCGA dataset. 
Similarly increase in mean copy number of SHH (R.E=8.2±3.7, p<0.0001), DHH (R.E=6.5±4.4, p<0.05) 
and GLI1 (R.E=6.6±3.9, p<0.05) were associated with presence of lymph node involvement in Pakistani 
cohort. Similarly, patients having distant metastasis significantly demonstrated enhanced SHH, DHH and 
GLI1 expression with highest levels of DHH (R.E=17.1±2.2, p<0.01) shown in the figure 2. 
Association of hedgehog pathway with ER, PR, Ki67 and HER2 
In Pakistani cohort, all hedgehog molecules were strongly related to hormonal receptors (ER and PR) (r-
value ranging from 0.71 to 0.87, p<0.05). However, majority of hedgehog molecules did not show any 
significant correlation with HER2 as shown in supplementary table 2. A strong positive correlation was 
established between Ki-67 proliferation index and SHH, DHH, PTCH1 and GLI1 (r-value ranging from 
0.60 to 0.78, p<0.05) indicating their putative role in cell proliferation. 
Correlation of Hedgehog Pathway with Molecular Subtypes of Breast Cancer 
In TCGA dataset, triple negative subtype of patients showed significant over expression of DHH, PTCH1 
and SMO. Following St. Gallen International Expert Consensus System, Pakistani cohort retains highest 
proportion of luminal-B (53%), followed by triple negative (18%), luminal-A(15%) and HER2 (14%) 
individuals. Both luminal B and triple negative subtypes representing patients showed significantly 
increase of SHH, DHH, PTCH1and GLI1 as shown in the fig 3.Furthermore,prognostic role of hedgehog 
pathway was assessed using the online available Kaplan Meier Plotter dataset (n=626 patients, follow-up 
threshold=15yrs) [17]. Elevated expression of hedgehog pathway members was also associated with 
shorter distance metastasis free survival in patients diagnosed with luminal-B breast cancer patients as 
shown in the supplementary figure 3. 
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High expression of SHH, DHH and GLI1 is poor predictor of overall survival 
Due to prospective nature of study design, follow-up data for overall survival was collected for 36 to 40 
months. Kaplan-Meier plots were generated using high and low expression of SHH, DHH and GLI1(Fig. 
3). Log-rank test was used to assess the effect of expression of SHH (HR=2.97 (1.6-5.6), p=0.0007), 
DHH (HR=2.25 (1.2-4.4), p=0.02) and GLI1 (HR= 4.06(2.2-7.5), p< 0.0001) which were all associated 
with poor predicted mortality. Based on univariate and multivariate Cox’s proportional regression 
analyses, elevated expression of SHH (HR=3.94 (1.7-9.4), p=0.002), DHH (HR=2.72 (1.2-6.5), p=0.02) 
and GLI1 (HR=4.5 (2.2-9.4), p<0.0001) were found to be independent predictor of overall survival. 
Furthermore patients having ER positive tumours (HR=3.05 (1.36-6.89), p=0.007) and distant metastasis 
(HR=3.47 (1.2-9.7), p=0.02) were found to be associated with shorter overall survival. Age (HR=0.18 
(0.07-0.44), p=0.0003) was also found to be a significant predictor of mortality having association of 
older age with less hazard ratio and good prognosis (table 2). Overall high expression of SHH, DHH and 
GLI1 was found to be an independent predictor of poor mortality in the present cohort. 
GANT61 mediated metastasis restriction by decreasing cell proliferation 
Earlier, effect of GANT61 in suppressing hedgehog pathway was assessed by measuring SHH, PTCH1 
and GLI1 expressions using qPCR and western blot. GANT61 effectively inhibited GLI1 (R.E=0.2±0.1 in 
MDA-MB-231 and R.E=0.2±0.17 in MCF-7, p<0.05). Being targets of GLI1,expression of SHH 
(R.E=0.18±0.2 in MDA-MB-231 and R.E=0.3±0.4 in MCF-7, p<0.05) and PTCH1 (R.E=0.09±0.14 in 
MDA-MB-231 and R.E=0.3±0.4 in MCF-7, p<0.05) were also repressed after treatment with GANT61 as 
shown in the figure 4.GANT61 significantly inhibited proliferation of MDA-MB-231 and MCF-7 cells in 
a dose and time-dependent manner from their respective control groups (p<0.0001) as mentioned in figure 
5. IC50 calculated for GANT61 (10µM) was used for migration and invasion assays.  
GANT61 reduced metastatic potential by decreasing cell migration and invasion 
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Furthermore, effect of hedgehog signaling on motility of breast cancer cells using an in vitro wound-
healing assay. MDA-MB-231 and MCF-7 cells were treated with pre-conditional medium containing 
GANT61 (10 µM) and control medium containing DMSO. GANT61 inhibited cell migration in both cell 
lines in contrast to their respective control cell lines (p<0.0001) as shown in the fig.5. Moreover, the 
effect of hedgehog signaling on the invasive ability of breast cancer cells was also evaluated using 
matrigel invasion assay. The ability of breast cancer cells to invade matrigel was markedly reduced in 
cells that were treated with GANT61 (p<0.0001), suggesting that hedgehog signaling has an essential role 
in the migration and invasiveness of breast cancer cells. 
Discussion 
Expression pattern of all aforementioned genes of hedgehog pathway are in line with earlier studies in 
different cancers [18–21]. Interestingly, lack of IHH association with clinical parameters is also observed 
in breast and prostate cancers [22,23] in line with the given cohort. However, up regulation of IHH 
observed among Chinese breast cancer cohort is contradictory to our findings [24]. This may be attributed 
to population specific genotypic variations, multiple hedgehog ligands targeting PTCH1 and sensitivity of 
detection technique. 
Over-expression of SHH, DHH and GLI1 was frequently observed in triple negative and luminal-B 
subtypes of the given cohort. In triple negative patients, activated hedgehog pathway was significantly 
related with advanced tumour stages and poor prognosis as has already been reported [25,26]. Hence 
suppression of hedgehog pathway may provide a novel therapeutic strategy for treating TNBC. On the 
other hand, association of hedgehog pathway with luminal subtypes can also be explained based on 
positive correlation of different hedgehog molecules with ER in the cohort. Co-expression of ER and 
SHH was present among 60% of the cohort patient’s, indicating molecular crosstalk as mentioned 
previously [27]. Similarly, strong positive correlation between hedgehog members (DHH, SHH, GLI1) 
and high Ki-67indexwith values 75, 80 and 85% respectively was observed. These findings corroborate 
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interplay of hedgehog pathway in tumour growth of luminal B subtype patients. Earlier it has been shown 
that inhibition of GLI1 expression via RNAi mediated depletion restricted cell growth in ER positive 
tamoxifen resistant cells [28]. Furthermore, role of hedgehog pathway towards tumourigenesis in 
endocrine therapy resistant patients has also been established [29].Based on these findings, inclusion of 
hedgehog pathway as novel therapeutic target in treating patients belonging to both TNBC and luminal-B 
subtypes is strongly recommended. 
Generally, aggressive molecular subtypes noted among young women are associated with worse outcome 
[30]. Hence, identification of alternate predictive and therapeutic biomarker is a necessity for these young 
patients. In the given study, alteration of hedgehog pathway was frequently observed among young 
Pakistani patients. Keeping in view increasing incidence of breast cancer in Pakistani women, devising 
novel therapeutic strategies are an absolute requirement. In the given cohort, patients<45yrs showed 
frequent over expression of SHH, DHH and GLI1 contributing towards aggressive tumourigenesis. 
Interestingly earlier findings also indicate that pre-menopausal patients showed more aggressive tumour 
progression in comparison to post menopausal population [31]. Hence elevated expression of SHH, DHH 
and GLI1 was also observed in pre-menopausal patients signifying their association with poor prognosis. 
Thus it is necessary to adapt a molecular screening driven approach to refine treatment for younger breast 
cancer patients including hedgehog inhibitors in adjuvant therapy regimen.  
Over-expression of SHH, DHH and GLI1 was significantly correlated with advanced stages and tumour 
grades of the cohort. Activation of hedgehog pathway in advance cancer stages has been reported 
previously in breast [25,32], ovarian [18], renal [19] and prostate cancer [10].Concomitantly, 
dysregulation of SHH, DHH and GLI-1 in the cohort has also been related with nodal involvement and 
metastasis. In another study, significant relevance of hedgehog ligands with metastasis and breast cancer 
specific death has been reported [33]. Similar results were obtained at both mRNA and protein levels in 
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Taiwanese and German populations [6,34].These findings strongly suggest role of hedgehog pathway in 
breast cancer progression and metastatic spread. 
High expression of SHH, DHH and GLI1 was also found to be an independent predictor of overall 
survival in this cohort along with age, distant metastasis and ER expression. However, SMO has a limited 
clinical relevance as observed in this cohort. No significant association of SMO with patient’s age, 
metastasis or other relevant parameters has been established in this study. Although, numerous SMO 
inhibitors like GDC-0449 (Vismodegib) have entered clinical trials for triple negative breast cancer 
patients but their efficacy still remains uncertain. Benvenuto et al. have recently proven that targeting 
hedgehog pathway using antagonists like GANT61 that act downstream of SMO is a more efficient 
strategy than using antagonists against SMO in breast cancer [35]. Furthermore non-canonical 
transcriptional activation of hedgehog pathway has also been extensively documented [36]. Hence, role of 
GANT61 as potential inhibitor of GLI1 against metastatic cascade has been deciphered. In this study, 
IC50 determined for both MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) cell lines, was 10µM. It showed 
maximum reduction of cell proliferation after 48hrs. This concentration of GANT61 was enough to 
suppress expression of GLI1 and transcriptional activation of PTCH1 and SHH as mentioned earlier [35]. 
Furthermore, GANT61 significantly reduced both motility and invasion thus efficiently demonstrating its 
potential to restrict cancer metastasis. 
Expression analysis of hedgehog pathway at early stage is highly recommended especially for young 
patients. Furthermore, this is the first ever report regarding evaluation of GANT61 potential role on 
metastasis suppression. Clinical and in-vitro functional assays findings strongly emphasize on hedgehog 
pathway’s putative role as potential cancer therapeutic target in breast cancer patients. 
Materials and Methods 
Publicly available expression data assessment 
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Pre-evaluation of hedgehog pathway in breast cancer datasets of two publicly available repositories 
namely, Oncomine and cBioportal were performed. Oncomine (Compendia Bioscience, Ann Arbor, 
MI; www.onocomine.org) is an online database consisting of earlier published 715 microarray datasets. 
RNA expression status of SHH, DHH, IHH, PTCH1, SMO and GLI1 genes were evaluated in 593 TCGA 
breast cancer samples and 59 Finak breast cancer samples available in Oncomine database. In order to 
score gene as positive (high expression) or negative (low expression), the Log2 Median-Centered ratio, as 
reported in the Oncomine database, was used to evaluate differential expression of these genes in different 
clinical groups.  
Similarly, cBioportal for Cancer Genomics (www.cbioportal.org)an online publicly available database, 
was screened in extended TCGA dataset of 1105 breast cancer patients[11]. RNAseq data of TCGA 
cohort was explored to validate expression pattern of SHH, DHH, IHH, PTCH1, SMO and GLI1. 
Clinical characteristics of the cohort  
The study proceeded with prior approvals from biosafety and ethical committees of both COMSATS 
Institute of Information Technology and Holy Family Hospital Rawalpindi, Pakistan. Informed consents 
from the participants were collected after a thorough briefing of the proposed research. Tumour biopsies 
(n=150) along with adjacent normal mammary tissues (n=150) were collected immediately after surgery 
and snap frozen till further usage. Data regarding clinical and pathological findings were obtained in 
subsequent follow-up from respective laboratory reports and consultation.  
RNA isolation and cDNA synthesis 
RNA isolation was performed with TRIzol® (15596-018, Invitrogen, USA) from the respective biological 
specimens following manufacturer’s instructions. Briefly, 1cm3 tissue section was homogenized using a 
hand held homogenizer in ice-cold RNA extraction buffer. Concentration of RNA was determined using 
nanodrop (Nanophotometer®Pearl, Implen, Germany). cDNA was synthesized using Revert Aid First 
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Strand cDNA Synthesis Kit (K1622, Thermo Scientific, USA).  
Quantitative Real-time PCR 
Primers for hedgehog pathway genes (SHH, DHH, IHH, PTCH1, SMO and GLI-1) were designed and 
synthesized from Integrated DNA Technology. β-actin was used to normalize the data. Sequences along 
with their amplicon sizes are provided in the supplementary table 1. Furthermore, primers for biomarkers 
ER (Estrogen receptor), PR (Progesterone receptor), HER-2 (Human Epidermal growth factor Receptor 2) 
and Ki-67 (Proliferative marker) used for molecular subtyping of breast cancer were also synthesized 
from IDT. VeriQuest SYBR Green qPCR Master Mix (75600200RXN, Thermo Scientific, USA) was 
used for qPCR in Step One plus (Applied Biosystem, USA). Reaction conditions included an initial 
denaturation at 95°C for 15min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 
55°C for 1min in each cycle. Relative mRNA expression was calculated using the 2−ΔΔCt method. 
QCanvas was used for the hierarchical clustering and visualizing heatmap of SHH, DHH, IHH, PTCH 
and SMO based on relative expression values [12]. 
Immunohistochemistry 
Immunohistochemical staining was done using both tumour and normal frozen sections of 4μm thickness 
of given cohort bio-specimens. Initially, these slices were mounted on Super Frost Plus microscopic 
slides and air-dried for 30min.These fixed tissue sections were treated with 50% methanol and 50% 
acetone for 15 min. Sections were then air dried for10 min and stored at -20˚C (wrapped in foil) till 
further usage. Briefly, these slides were placed in PBS for 5 min to rehydrate, followed by blocking with 
10% horse serum. These sections were later exposed with primary antibodies for SHH, DHH and 
GLI1.Antibodies used were rabbit anti-SHH polyclonal antibody (H-160; sc-9024, dilution 1:200; Santa 
Cruz Biotechnology, USA), mouse monoclonal anti-DHH (sc-271168, dilution 1:200; Santa Cruz 
Biotechnology, USA) and mouse anti-GLI1 monoclonal antibody (D1; sc-271075, diluted 1:200; Santa 
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Cruz Biotechnology, USA). Exclusion of primary antibody acted as a negative control. Immunostaining 
was performed as previously described [13]. Immuno-Reactive-Scores (IRS) were evaluated as the 
product of  % of cells positively stained for each molecule categorized from 1 to 4 (1=<25%, 2=25-
50%,3>50%). Final IRS scores were ranked as high or low based on mean of IRS. Expression of pathway 
molecules was correlated with demographic and clinico-pathological findings of the cohort.  
Breast cancer cell lines maintenance and culture condition 
Breast cancer cell lines (MCF-7 and MDA-MB-231) were generously provided by Dr Yi Li (Breast centre 
Li, Baylor College of Medicine, USA). These lines were cultured and maintained as recommended by 
ATCC. Role of hedgehog pathway towards metastasis was assessed in these cell lines by inhibiting 
downstream effector GLI via GANT61 (G9048-5MG, Sigma, Germany). 
Western blot analysis 
Cells were homogenized in lysis buffer containing protease inhibitor. Concentration of the harvested 
proteins was determined using the Pierce BCA (Bicinchoninic Acid) protein assay kit (23225, Thermo 
Scientific, USA). Western blotting was performed following protocol described previously [14]. Both 
primary and secondary antibodies used for this study were purchased from Santa Cruz Biotechnology 
(USA) unless stated otherwise. Human SHH (H-160; sc-9024, dilution 1:1000), human PTCH-1 (H-267; 
sc-9016, dilution1:500), human GLI-1 (H-300; sc-20867, dilution 1:1000) were used. Rabbit polyclonal 
antibody was used as secondary antibody for these blots. Mouse monoclonal antibody targeting against 
human Actin (C-4; sc-47778, dilution 1:3000) was used as control. The experiments were repeated three 
times independently. 
Cell proliferation assay 
The cell proliferation assay was assessed with CCK-8 (CK04-05, Dojindo, Japan) as reported [15]. 
Briefly, triplicate sets of 96 well plates retaining 5x103cells from both MDA-MB-231 and MCF-7 cell 
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lines were prepared. After exposure with variable concentration (0, 5µM, 10 µM, 15 µM and 20µM) of 
GANT61, these plates were incubated at 37°C retaining 5% CO2 for 48hrs. Assay was repeated at least 
three times to validate IC50 value for GANT61. Furthermore, time dependent effect of GANT61 was 
evaluated at different time points (0, 24, 48, 72 and 96hrs). 
Cell invasion assay 
Using inserts of 8μm size placed in 24’ well plate, invasion assays were performed. Briefly, each insert 
was initially coated with Matrigel (356234, BD MatrigelTM Basement Membrane Matrix, BD Biosciences, 
UK). After rehydration, 5x104 cells of respective cell lines were seeded separately in the insert. Two set of 
inserts were used for each cell line. Cells in one insert were exposed to DMSO (Dimethyl sulfoxide) as 
control while in other insert GANT61 (10µM) was added. After 24hrs of incubation, inserts were fixed 
with formalin and stained in crystal violet [14].Cells were counted under microscope to observe any 
possible invasion as mentioned (14). 
Cell migration assay 
A wound of ~300µm was artificially introduced into monolayer of breast cancer cell line and cells 
movement towards the wound was measured over span of 48hrs. Effect of GANT61 exposure towards 
cells motility was also calculated in these cell lines. Images were taken through a phase-contrast 
microscope (10× objective lens) at 0, 12, 24, 36 and 48hrs. The wound area was quantified with the 
Image J software [16]. Data was expressed as the mean of three independent experiments ± standard 
deviation. 
Statistical analysis 
Wilcoxon signed rank test was used to evaluate difference between tumours and adjacent controls. Mann 
Whitney and Kruskal-Wallis Anova were applied to assess the association of molecules with different 
clinico–pathological parameters. Spearman correlation was also used to evaluate relationship between all 
15 
 
molecules in tumourigenesis. Unpaired t-test was applied to assess statistical differences in cell 
proliferation, migration and invasion assays. Kaplan-Meier plots were generated and survival was 
compared using log rank test. Cox's proportional hazard regression analyses were performed to evaluate 
hazard ratio of covariates for overall survival of patients. Statistical analyses were performed using 
Graphpad Prism 5 (GraphPad Software, Inc. CA, USA) and StatsDirect (http://www.statsdirect.com. 
StatsDirect Ltd. 2013, England).The value for p<0.05 was considered significant. 
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List of Figure Legends 
Figure 1: Expression Profiling of Hedgehog Pathway Members in Pakistani Cohort. 
a). Scatter plots showing mean relative mRNA expression of SHH, DHH, IHH, PTCH1, SMO 
and GLI1 in tumor samples as compared to normal tissues. b). Heatmap showing differential 
expression of analyzed molecules in tumors on left side and adjacent normal mammary tissues 
on right side. c). Immunostaining of SHH (A, B), DHH (C, D) and GLI1 (E, F) in normal tissues 
(A, C, E) and tumor tissues (B, D, F). (Wilcoxon Signed Rank Test, p<0.0001).  
Figure 2: Transcript Profiling of Hedgehog Pathway using Box Whisker Plots.  
Association of relative expression of hedgehog pathway components with a). Nuclear grades, b). 
Tumor size, c). Nodal involvement, d). Metastasis, e). Age at disease onset, f). Menopausal 
status. (Kruskal-Wallis Anova (a, b and c) and Mann-Whitney U test (d, e and f), * p<0.05, ** 
p<0.001, ***p<0.0001).  
Figure 3: Correlation of Hedgehog molecules with Intrinsic Molecular Subtypes and Overall 
Survival of patients.   
a). Expression variation of hedgehog pathway in molecular subtypes (Luminal A, Luminal B, 
HER2 and Triple negative) of breast cancer patients evaluated using qPCR. (Kruskal-Wallis 
Anova, * p<0.05, ***p<0.0001). b). Kaplan Meier plots showing association of SHH, DHH and 
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GLI1 with Overall survival in Pakistani population (red = high expression, blue = low 
expression, significant p<0.05). 
Figure 4: Effect of GANT61 exposure on SHH, PTCH1 and GLI1 using qPCR and 
Western blot. 
Inhibition of expression of hedgehog pathway after treatment with GANT61 (10µM) for 48hrs. 
Relative mRNA expression of SHH, PTCH1 and GLI1 using qPCR in a). MDA-MB-231, b). 
MCF-7 (Mann Whitney U test, * p<0.05, ** p<0.001, ***p<0.0001). c). Protein expression of 
SHH, PTCH1 and GLI1 using western blot having β-actin as internal control in both cell lines. 
All experiments were conducted in triplicates and were performed thrice. 
Figure 5: Effect of GANT61 on proliferation, motility and invasion of breast cancer cells.  
Inhibitory effect of GANT61 on proliferation, motility and invasion of breast cancer cells was 
tested using in vitro models. Cell viability assays were conducted using CCK-8, to observe the 
effect of GANT61 on cell proliferation in MDA-MB-231 and MCF-7 in a). Dose dependent (5, 
10, 15, 20µM) and b). Time dependent manner (24, 48, 72, 96hrs). IC50 of GANT61 was 
determined to be 10 µM.  MDA-MB-231 and MCF-7 were treated with the conditional medium 
containing 10uM GANT61 and the control medium. c). Migration was assessed using scratch 
assay and readings were taken after every twelve hour for 48hrs, upper panel of both cell lines 
represent 0hr and the lower panel represents 48hr. d). Graph showing difference of distance 
migrated between untreated and treated cells at each time point of scratch assay. e). Invasion was 
assessed using Boyden chamber transwell assays and difference between treated and untreated 
cells was evaluated after 24hrs. d). Graphical representation of number of cells invaded as mean 
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± S.D. between untreated and treated cells in both cell lines. (Unpaired t test, ***, ### 
p<0.0001). All experiments were conducted in triplicates and were performed thrice. 
 
 
 
 
 
 
 
 
 
 
 
Tables 
Table 1: Clinical correlation of hedgehog pathway with demographic and pathological variables in 
Pakistani breast cancer cohort. 
Variable Total Mean±SD 
SHH p-value DHH p-value IHH p-value PTCH p-value SMO p-value GLI-1 p-value 
Tumour 150 4.4±3.3 < 0.0001 4.7±3.5 < 0.0001 0.04±0.2 < 0.0001 3.4±3.1 < 0.0001 1.4±2.1 0.61 3.8±2.5 < 0.0001 
Control 150 1.0±0.9 1.0±1.4 1.0±1.1 1.0±1.0 1.0±1.3 1.0±0.8 
Disease onset age 
Age ≤ 45 years 76 5.6±3.9 0.03 5.5±4.2 0.04 0.2±0.8 0.65 3.2±3.1 0.26 
 
1.9±2.2 0.03 6.3±4.5 0.03 
Age  ≥ 45 years 74 4.2±3.3 3.9±2.9 0.04±0.2 3.6±3.0 1.2±1.8 4.2±2.7 
Menopausal status 
Pre-Menopausal 80 6.8±4.8 0.0065 5.6±3.9 0.01 0.23±0.8 0.45 0.2±0.8 < 0.0001 2.8±3.6 0.12 7.9±4.3 < 0.0001 
Post-Menopausal 70 4.5±3.5 3.9±3.0 0.05±0.2 3.9±3.3 2.1±3.1 3.9±2.5 
Laterality 
Right 75 4.2±2.8 0.01 5.8±4.0 0.001 0.2±0.8 0.13 3.4±2.9 0.97 2.5±2.9 0.26 4.5±2.9 0.02 
Left 75 6.1±4.1 3.8±3.0 0.1±0.4 3.4±3.2 2.1±3.1 6.4±4.5 
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Table 2: Univariate and multivariate Cox's proportional hazard regression analyses of Pakistani 
breast cancer cohort for potential predictors of overall survival 
Characteristics Univariate analysis Multivariate analysis 
HR(95%CI) p value HR(95%CI) p value 
SHH  3.14(1.3-7.7) 0.01 
Age 0.18(0.06-0.45) 0.0003 0.2(0.08-0.56) 0.002 
SHH 3.89(1.6-9.2) 0.002 
ER 2.67(1.2-6.0) 0.02 2.26(0.97-5.25) 0.05 
SHH 3.53(1.5-8.4) 0.004 
PR 1.76(0.9-3.5) 0.09 - - 
SHH 3.58(1.5-8.6) 0.004 
HER-2 1.16(0.6-2.1) 0.6 - - 
SHH 3.93(1.7-9.3) 0.002 
Metastasis 2.96(1.1-8.3) 0.03 2.62(1.3-5.3) 0.007 
SHH 3.79(1.6-9.0) 0.002 
DHH  2.83(1.2-6.8) 0.02 
Grade-wise distribution 
Grade I 14 3.5±2.7 0.0001 3.4±2.4 0.48 0.2±0.9 0.2 2.9±2.9 0.68 2.4±3.5 0.11 2.8±1.9 0.01 
 Grade II 90 5.0±3.8 4.9±3.7 0.2±0.6 3.4±3.2 2.6±3.2 3.2±1.8 
Grade III 46 9.4±6.5 4.9±3.6 0.09±0.3 3.6±3.2 2.1±3.6 5.6±4.3 
Stage-wise distribution 
Stage I 34 4.2±3.3 < 0.0001 6.2±3.6 < 0.0001 0.1±0.5 0.03 3±2.8 0.35 2.6±3.3 0.09 6.7±3.9 0.005 
 Stage II 68 7.1±4.1 8.3±3.7 0.2±0.7 3.3±3.2 2.3±2.7 7.2±3.6 
Stage III 43 8.7±3.9 8.6±3.8 0.1±0.2 3.6±2.9 1.3±1.7 7.9±3.8 
Stage IV 5 14.6±2.9 17±2.2 0.06±0.1 4.9±2.8 2.3±1.9 14.5±3 
Nodal Involvement 
N0 (none) 48 4.3±3.2 < 0.0001 3.3±2.8 0.01 0.2±0.5 0.02 2.9±3 0.34 2.6±3.2 0.92 4.1±2.7 0.003 
N1(lymph node<4) 78 6.1±4.1 5.8±4.2 0.2±0.7 3.6±3.2 2.3±3.3 5.9±3.6 
N2(lymph node>4) 24 8.2±3.7 6.5±4.4 0.006±0 3.6±2.8 2.7±3.9 6.6±3.9 
Distant Metastasis 
M0 145 4.4±3.4 0.0003 4.5±3.4 0.0002 0.14±0.6 0.09 3.3±3.0 0.12 2.4±3.4 0.34 3.8±2.5 0.0002 
 M1 5 14.6±2.9 17±2.2 0.06±0.1 4.9±2.8 2.3±1.8 14.5±3 
Molecular subtypes 
HER-2  21 2.7±2.4 < 0.0001 2.2±1.1 < 0.0001 0.03±0.1 0.73 4.3±4.5 0.04 2.5±3 0.63 3.7±2.1 0.0007 
 
 
Luminal A 23 5.3±2.8 1.9±1.6 0.06±0.2 2.1±1.9 1.9±2.7 2.7±1.6 
Luminal B 79 6.7±2.7 4.9±3.5 0.1±0.4 3.7±3 2.6±3.4 5.2±2.9 
Triple Negative 27 5.9±3.2 2.9±2.6 0.3±0.8 4.1±3.8 1.8±2.8 3.8±2.5 
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Age 0.16(0.07-0.43) 0.0002 0.17(0.1-0.5) 0.0003 
DHH 2.94(1.2-6.9) 0.01 
ER 2.78(1.2-6.3) 0.01 2.00(0.8-4.9) 0.13 
DHH 2.42(1.0-5.8) 0.04 
PR 1.97(1.0-3.85) 0.05 2.04(0.97-4.3) 0.06 
DHH 2.56(1.1-6.1) 0.03 
HER-2 1.16(0.6-2.1) 0.62 - - 
DHH 2.72(1.2-6.5) 0.02 
Metastasis 3.97(1.9-7.9) 0.0001 2.9(1.4-5.9) 0.003 
DHH 3.16(1.3-7.5) 0.009 
GLI1  3.67(1.7-7.9) 0.0008 
Age 0.17(0.07-0.43) 0.0002 0.18(0.1-0.5) 0.0004 
GLI1 4.67(2.2-9.8) <0.0001 
ER 2.43(1.1-5.5) 0.03 2.45(1.1-5.6) 0.03 
GLI1 3.98(1.9-8.4) 0.0003 
PR 1.26(0.6-2.6) 0.52 - - 
GLI1 4.15(1.9-9.1) 0.0004 
HER-2 1.01(0.5-1.9) 0.98 - - 
GLI1 4.51(2.2-9.5) <0.0001 
Metastasis 2.54(1.3-5.1) 0.009 1.85(1.9-3.8) 0.009 
GLI1 4.01(1.9-8.5) 0.0003 
Bold values show significance at p<0.05, covariates significant in univariate analyses were considered for multivariate analyses.  
 
 





